Clinical trials
Phase 2 Vaginosis, Bacterial trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Not yet recruiting | 2 |
| Unknown status | 2 |
| Recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Guangdong Longchuangji Pharmaceutical Co., Ltd. | 2 |
| Starpharma Pty Ltd | 2 |
| Alfasigma S.p.A. | 1 |
| Centers for Disease Control and Prevention | 1 |
| Chengdu Syncor Pharmaceutical Co., Ltd. | 1 |
| Douglas Kwon | 1 |
| Freya Biosciences ApS | 1 |
| Graceway Pharmaceuticals, LLC | 1 |
| Haudongchun Co., Ltd. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vaginosis, Bacterial | 24 |
| Vaginitis | 4 |
| Candidiasis | 2 |
| Candidiasis, Vulvovaginal | 2 |
| Birth Weight | 1 |
| Chorioamnionitis | 1 |
| Gonorrhea | 1 |
| HIV Infections | 1 |
| Infections | 1 |
| Infertility, Female | 1 |
Trials
Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.